# A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05914116/  
OnCo record `nct05914116` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BNT324 and Enzalutamide in advanced solid tumours, run by DualityBio Inc., now recruiting.

## Summary

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05914116 by DualityBio Inc., with 862 participants planned, started 2023-08-17 and due to reach its primary completion in 2027-12. Interventions recorded: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide and Abiraterone.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05914116
- Phase: 1/2
- Setting: A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors
- Sponsor: DualityBio Inc.
- Enrolled: 862

## Sources

- ClinicalTrials.gov NCT05914116: https://clinicaltrials.gov/study/NCT05914116

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [BNT324](https://onco.cc/drugs/bnt324/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Duality Biotherapeutics](https://onco.cc/companies/dualitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct05914116.json